Factor XI and contact activation as targets for antithrombotic therapy.
Nashville, United States. In J Thromb Haemost, Aug 2015
Attention has focused on FXII, the zymogen of a protease (FXIIa) that initiates contact activation when blood is exposed to foreign surfaces, and FXI, the zymogen of the protease FXIa, which links contact activation to the thrombin generation mechanism.
Novel products for haemostasis.
Kashihara, Japan. In Haemophilia, 2014
Several specific plasma-derived or recombinant products including fibrinogen, FVIIa, FXI and FXIII have now become available, however, and a phase III clinical study of recombinant FXIIIa has recently been completed demonstrating safety and efficacy of substances of this nature.
Congenital factor XI deficiency: an update.
Milano, Italy. In Semin Thromb Hemost, 2013
Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous mutations).
Gene variants associated with deep vein thrombosis.
Leiden, Netherlands. In Jama, 2008
In the region of CYP4V2, we identified 4 additional SNPs (in CYP4V2, KLKB1, and F11) that were also associated with both DVT (highest OR per risk allele, 1.39; 95% CI, 1.11-1.74)
Frequency of inherited bleeding disorders in women with menorrhagia.
London, United Kingdom. In Lancet, 1998
The activated partial thromboplastin time, factor VIII activity, von-Willebrand-factor antigen and activity, and factor XI (FXI) were measured in all patients; further tests were done when results were at or outside the limits of the assays.